
At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.

Rebecca Khan, MD, FACOG, practiced obstetrics and gynecology for 21 years before serving as the director of women’s health for BioReference® Laboratories, LLC. Currently, Khan works in medical affairs at Thermo Fisher Scientific with a focus on placental biomarkers, sFlt-1 and PlGF.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
